Receptor Occupancy-based Analysis of the Contributions of Various Receptors to Antipsychotics-induced Weight Gain and Diabetes Mellitus

Drug Metabolism And Pharmacokinetics

Volumn 20, Issue 5, 2005, Pages 368-378

  Matsui Sakata, Akiko ^a   Ohtani, Hisakazu ^b   Sawada, Yasufumi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

diabetes mellitus; histamine H1receptor; receptor occupancy theory; typical and atypical antipsychotics; weight gain

Indexed keywords

ADRENERGIC RECEPTOR; DOPAMINE 2 RECEPTOR; DRUG RECEPTOR; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN 2C RECEPTOR;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; META ANALYSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; META-ANALYSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, ADRENERGIC; RECEPTORS, DOPAMINE D2; RECEPTORS, DRUG; RECEPTORS, HISTAMINE H1; RECEPTORS, MUSCARINIC; WEIGHT GAIN;

EID: 33644684681     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.20.368     Document Type: Article

References (76)

1. Planansky, K.: Changes in weight gain in patients receiving a átranquilizingá drug. Psychiatr. Q., 32: 289-303 (1958).
2. Amdisen, A.: Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan. Med. Bull., 11: 182-189 (1964).
3. Klett, C. J. and Caffey, E. M. Jr.: Weight changes during treatment with phenothiazine derivatives. J. Neuropsychiatr., 2: 102-108 (1960).
4. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C. and Weiden, P. J.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry, 156(11): 1686-1696 (1999).
5. Knight, A.: Astemizoleáa new, non-sedating antihistamine for hayfever. J. Otolaryngol., 14(2): 85-88 (1985).
6. Wilson, J. D. and Hillas, J. L.: Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis. Clin. Allergy., 13(2): 131-140 (1983).
7. Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F. and Julius, D.: Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 374(6522): 542-546 (1995).
8. Stanton, J. M.: Weight gain associated with neuroleptic medication: a review. Schizophr. Bull., 21(3): 463-472 (1995).
9. Okada, T.: Glucose intolerance associated with novel antipsychotics. Rinsyoseishinyakuri, 5: 1405-1412 (2002).
10. Cooperberg, A. A. and Eidlow, S.: Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy. Can. Med. Assoc. J., 75(9): 746-749 (1956).
11. Korenyi, C. and Lowenstein, B.: Chlorpromazine induced diabetes. Dis. Nerv. Syst., 29(12): 827-828 (1968).
12. Chakraborty, B. S., Midha, K. K., McKay, G., Hawes, E. M., Hubbard, J. W., Korchinski, E. D., Choc, M. G. and Robinson, W. T.: Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study. J. Pharm. Sci., 78(10): 796-801 (1989).
13. Leucht, S., Pitschel-Walz, G., Abraham, D. and Kissling, W.: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A metaanalysis of randomized controlled trials. Schizophr. Res., 35(1): 51-68 (1999).
14. Zoler, M. L.: Antipsychotics linked to weight gain, diabetes. Clinical Psychiatry News, 27: 20 (1999).
15. Sawada, Y., Yamada, Y. and Iga, T.: Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory. Yakugaku Zasshi, 117(2): 65-90 (1997).
16. Matsui-Sakata, A., Ohtani, H. and Sawada, Y.: Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release. Drug Metab. Pharmacokinet., 20(3): 187-199 (2005).
17. Mercer, L. P., Kelley, D. S., Humphries, L. L. and Dunn, J. D.: Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J. Nutr., 124(7): 1029-1236 (1994).
18. Fukagawa, K., Sakata, T., Shiraishi, T., Yoshimatsu, H., Fujimoto, K., Ookuma, K. and Wada, H.: Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am. J. Physiol., 256(3 Pt 2): R605-R611 (1989).
19. Inoue, I., Yanai, K., Kitamura, D., Taniuchi, I., Kobayashi, T., Niimura, K., Watanabe, T. and Watanabe, T.: Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc. Natl. Acad. Sci. USA., 93(23): 13316-13320 (1996).
20. Masaki, T., Yoshimatsu, H., Chiba, S., Watanabe, T. and Sakata, T.: Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes, 50(2): 385-391 (2001).
21. Mollet, A., Lutz, T. A., Meier, S., Riediger, T., Rushing, P. A. and Scharrer, E.: Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am. J. Physiol. Regul. Integr. Comp. Physiol., 281(5): R1442-R1448 (2001).
22. Morimoto, T., Yamamoto, Y., Mobarakeh, J. I., Yanai, K., Watanabe, T., Watanabe, T. and Yamatodani, A.: Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol. Behav., 67(5): 679-683 (1999).
23. Melkersson, K. I. and Hulting, A. L.: Insulin and leptin levels in patients with schizophrenia or related psychosesáa comparison between different antipsychotic agents. Psychopharmacology (Berl), 154(2): 205-212 (2001).
24. Lean, M. E. and Pajonk, F. G.: Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care., 26(5): 1597-1605 (2003).
25. Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J. and Marder, S. R.: Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatry, 60(6): 358-363 (1999).
26. Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y. and Roth, B. L.: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28(3): 519-526 (2003).
27. Nonogaki, K., Strack, A. M., Dallman, M. F. and Tecott, L. H.: Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med., 4(10): 1152-1156 (1998).
28. Blundell, J. E.: Serotonin and appetite. Neuropharmacology, 23(12B): 1537-1551 (1984).
29. Luo, S. Q. and Li, E. T.: Effects of repeated administration of serotonergic agonists on diet selection and body weight in rats. Pharmacol. Biochem. Behav., 38(3): 495-500 (1991).
30. Shionogi & Co., Ltd. (Japan): Package insert of Clorpromazine, (2005).
31. Forsman, A. and Ohman, R.: Studies on serum protein binding of haloperidol. Curr. Ther. Res. Clin. Exp., 21(2): 245-255 (1977).
32. Novartis Pharma K. K. (Japan).: Interview form of Thioridazine, (2000).
33. Nyberg, G., Axelsson, R. and Martensson, E.: Cerebrospinal fluid concentrations of thioridazine and its main metabolites in psychiatric patients. Eur. J. Clin. Pharmacol., 19(2): 139-148 (1981).
34. Dahl, S. G. and Strandjord, R. E.: Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin. Pharmacol. Ther., 21(4): 437-448 (1977).
35. Alfredsson, G., Wode-Helgodt, B. and Sedvall, G.: A mass fragmentographic method for the determination of chlorpromazine and two of its active metabolites in human plasma and CSF. Psychopharmacology (Berl), 48(2): 123-131 (1976).
36. Richelson, E. and Nelson, A.: Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur. J. Pharmacol., 103(3-4): 197-204 (1984).
37. Wander, T. J., Nelson, A., Okazaki, H. and Richelson, E.: Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur. J. Pharmacol., 143(2): 279-282 (1987).
38. Herrick-Davis, K., Grinde, E. and Teitler, M.: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther., 295(1): 226-232 (2000).
39. Choc, M. G., Lehr, R. G., Hsuan, F., Honigfeld, G., Smith, H. T., Borison, R. and Volavka, J.: Multiple-dose pharmacokinetics of clozapine in patients. Pharm. Res., 4(5): 402-405 (1987).
40. Schaber, G., Stevens, I., Gaertner, H. J., Dietz, K. and Breyer-Pfaff, U.: Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance. Br. J. Clin. Pharmacol., 46(5): 453-459 (1998).
41. Richelson, E. and Souder, T.: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci., 68(1): 29-39 (2000).
42. Schmidt, A. W., Lebel, L. A., Howard, H. R. Jr. and Zorn, S. H.: Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur. J. Pharmacol., 425(3): 197-201 (2001).
43. Schotte, A., Janssen, P. F., Gommeren, W., Luyten, W. H., Van Gompel, P., Lesage, A. S., De Loore, K. and Leysen, J. E.: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 124(1-2): 57-73 (1996).
44. Midha, K. K., McKay, G., Edom, R., Korchinski, E. D., Hawes, E. M. and Hall, K.: Kinetics of oral fluphenazine disposition in humans by GC-MS. Eur. J. Clin. Pharmacol., 25(5): 709-711 (1983).
45. Esumi, Y., Jin, Y., Sonobe, J. and Kamiya, K.: Metabolic fate of fluphenazine decanoate (1)áabsorption, distribution and excretion of 14C-labeled compounds in rats and dogs. Yakuri to Tiryo., 19(1): 67-85 (1991).
46. Nayak, R. K., Doose, D. R. and Nair, N. P.: The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J. Clin. Pharmacol., 27(2): 144-150 (1987).
47. Linkowski, P., Hubain, P., von Frenckell, R. and Mendlewicz, J.: Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur. Arch. Psychiatry Neurol. Sci., 234(4): 231-236 (1984).
48. Zetin, M., Cramer, M., Garber, D., Plon, L., Paulshock, M., Hoffman, H. E. and Schary, W. L.: Bioavailability of oral and intramuscular molindone hydrochloride in schizophrenic patients. Clin. Ther., 7(2): 169-175 (1985).
49. Freedberg, K. A., Innis, R. B., Creese, I. and Snyder, S. H.: Antischizophrenic drugs: differential plasma protein binding and therapeutic activity. Life Sci., 24(26): 2467-2473 (1979).
50. Ishigooka, J., Wakatabe, H., Murasaki, M. and Miura, S.: Phase I study of risperidone, a new antipsychotic drug of benzisoxazole derivative. Clinical Evaluation, 19(1): 93-163 (1991).
51. Mannens, G., Meuldermans, W., Snoeck, E. and Heykants, J.: Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl), 114(4): 566-572 (1994).
52. Wong, S. L., Cao, G., Mack, R. J. and Granneman, G. R.: Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin. Pharmacol. Ther., 62(2): 157-164 (1997).
53. Pfizer INC.: US Package insert of Ziprasidone, (2003).
54. Claghorn, J., Honigfeld, G., Abuzzahab, F. S. Sr, Wang, R., Steinbook, R., Tuason, V. and Klerman, G.: The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol., 7(6): 377-384 (1987).
55. Kane, J., Honigfeld, G., Singer, J. and Meltzer, H.: Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 45(9): 789-796 (1988).
56. Beasley, C. M. Jr., Sanger, T., Satterlee, W., Tollefson, G., Tran, P. and Hamilton, S.: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl), 124(1-2): 159-167 (1996).
57. Beasley, C. M. Jr., Tollefson, G., Tran, P., Satterlee, W., Sanger, T. and Hamilton, S.: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14(2): 111-123 (1996).
58. Tollefson, G. D., Beasley, C. M. Jr., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R. N., Graffeo, K. A. and Thieme, M. E.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry, 154(4): 457-465 (1997).
59. Beasley, C. M. Jr., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O. and Beuzen, J. N.: Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychopharmacol., 7(2): 125-137 (1997).
60. Ishigooka, J., Inada, T. and Miura, S.: Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin. Neurosci., 55(4): 403-414 (2001).
61. Borison, R. L., Arvanitis, L. A. and Miller, B. G.: ICI 204, 636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J. Clin. Psychopharmacol., 16(2): 158-169 (1996).
62. Small, J. G., Hirsch, S. R., Arvanitis, L. A., Miller, B. G. and Link, C. G.: Quetiapine in patients with schizophrenia. A high-and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch. Gen. Psychiatry, 54(6): 549-557 (1997).
63. Arvanitis, L. A. and Miller, B. G.: Multiple fixed doses of áSeroquelá (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry, 42(4): 233-246 (1997).
64. Peuskens, J. and Link, C. G.: A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta. Psychiatr. Scand., 96(4): 265-273 (1997).
65. King, D. J., Link, C. G. and Kowalcyk, B.: A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology (Berl), 137(2): 139-146 (1998).
66. Copolov, D. L., Link, C. G. and Kowalcyk, B.: A multicentre, double-blind, randomized comparison of quetiapine (ICI 204, 636, 'Seroquel') and haloperidol in schizophrenia. Psychol. Med., 30(1): 95-105 (2000).
67. Schooler, N. R.: Negative symptoms in schizophrenia: assessment of the effect of risperidone. J. Clin. Psychiatry, 55 Suppl: 22-28 (1994).
68. Peuskens, J.: Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry, 166(6): 712-726 (1995).
69. Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B. and Baumann, P.: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am. J. Psychiatry, 155(4): 499-504 (1998).
70. Nair, N. P.: Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. J. Clin. Psychopharmacol., 18(2): 103-110 (1998).
71. Wirshing, D. A., Marshall, B. D. Jr., Green, M. F., Mintz, J., Marder, S. R. and Wirshing, W. C.: Risperidone in treatment-refractory schizophrenia. Am. J. Psychiatry, 156(9): 1374-1379 (1999).
72. Heck, A. H., Haffmans, P. M., de Groot, I. W. and Hoencamp, E.: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res., 46(2-3): 97-105 (2000).
73. Conley, R. R. and Mahmoud, R.: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 158(5): 765-774 (2001).
74. van Kammen, D. P., McEvoy, J. P., Targum, S. D., Kardatzke, D. and Sebree, T. B.: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl), 124(1-2): 168-175 (1996).
75. Zimbroff, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., Sebree, T. B., Wallin, B. A. and Kashkin, K. B.: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am. J. Psychiatry, 154(6): 782-791 (1997).
76. Daniel, D. G., Zimbroff, D. L., Potkin, S. G., Reeves, K. R., Harrigan, E. P. and Lakshminarayanan, M.: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology, 20(5): 491-505 (1999).